Prostate volume measurement by transrectal ultrasound and computed tomography before and after permanent prostate brachytherapy

2004 ◽  
Vol 60 (3) ◽  
pp. 767-776 ◽  
Author(s):  
Matthew C. Solhjem ◽  
Brian J. Davis ◽  
Thomas M. Pisansky ◽  
Torrence M. Wilson ◽  
Lance A. Mynderse ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Prostate Volume ◽  
Transrectal Ultrasound ◽  
Volume Measurement ◽  
Prostate Brachytherapy ◽  
Before And After

Can we trust the prostate volume derived from computed tomography instead of transrectal ultrasound? Comparison of the prostate volumes on CT and TRUS images in permanent prostate brachytherapy

Brachytherapy ◽  
2008 ◽  
Vol 7 (2) ◽  
pp. 191
Author(s):  
Takeshi Arimura ◽  
Fumihiko Nakamura ◽  
Yoshiyuki Hiraki ◽  
Masayuki Nakajo ◽  
Hideki Enokida ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Prostate Volume ◽  
Transrectal Ultrasound ◽  
Prostate Brachytherapy

Impact of transrectal ultrasound- and computed tomography-based seed localization on postimplant dosimetry in prostate brachytherapy

Brachytherapy ◽  
2009 ◽  
Vol 8 (2) ◽  
pp. 255-264 ◽  
Author(s):  
Meng-Sang Chew ◽  
Jinyu Xue ◽  
Chris Houser ◽  
Vladimir Misic ◽  
Junsheng Cao ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Transrectal Ultrasound ◽  
Prostate Brachytherapy ◽  
Postimplant Dosimetry ◽  
Seed Localization

Predictive factors for acute and late urinary toxicities after permanent prostate brachytherapy.

2012 ◽  
Vol 30 (5_suppl) ◽  
pp. 90-90
Author(s):  
Ryuta Tanimoto ◽  
Kensuke Bekku ◽  
Yasuyuki Kobayashi ◽  
Shin Ebara ◽  
Motoo Araki ◽  
...  
Keyword(s):  
Predictive Factors ◽  
Prostate Volume ◽  
Univariate Analysis ◽  
Radiation Therapy Oncology Group ◽  
Target Volume ◽  
Prostate Brachytherapy ◽  
Factors Associated ◽  
Prostate Size ◽  
Before And After

90 Background: To describe the frequency of acute and late Radiation Therapy Oncology Group (RTOG) urinary toxicity associated with predictive factors and International Prostate Symptom Score (IPSS) in consecutive prostate brachytherapy patients. Methods: From January 2004 to April 2011, 466 patients underwent permanent 125I-seed brachytherapy (median follow-up, 48 months). The IPSS and RTOG toxicity data were prospectively collected. The prostate volume, IPSS before and after brachytherapy and postimplant analysis were examined for an association with urinary toxicity which was defined as urinary RTOG toxicity 1 or more. Logistic regression analysis was used to examine the factors associated with urinary toxicities. Results: The rate of RTOG urinary toxicity Grade 1 or more at 1, 6, 12, 24, 36, 48 months was 67%, 40%, 21%, 31%, 27%, 28%, respectively. Grade 2 or more urinary toxicities were less than 1% at an each point. IPSS was highest at 3 months and returned to normal level at 12 months after brachytherpapy. On univariate analysis, patients with larger prostate size, greater baseline IPSS, the higher post V100 (volume of the prostate covered by 100% of the dose), higher post V150 and higher post D90 (dose that 90% of the target volume received) had more acute urinary toxicities 1 month as well as 12 months after brachytherapy. On multivariate analysis, the significant predictors for urinary toxicities were a greater baseline IPSS and post V100 one month as well as 12 months after brachytherapy (shown below). Conclusions: Most urinary symptoms were tolerated and resolved within 12 months after prostate brachytherapy. Acute and late urinary toxicities after brachytherapy were strongly related with baseline IPSS and the post V100.

Prostate Volume Before and After Permanent Prostate Brachytherapy in Patients Receiving Neoadjuvant Androgen Suppression

2004 ◽  
Vol 10 (6) ◽  
pp. 343-348 ◽  
Author(s):  
Matthew C. Solhjem ◽  
Brian J. Davis ◽  
Thomas M. Pisansky ◽  
Torrence M. Wilson ◽  
Lance A. Mynderse ◽  
...  
Keyword(s):  
Prostate Volume ◽  
Prostate Brachytherapy ◽  
Before And After ◽  
Androgen Suppression

The Comparison of Imaging and Clinical Methods to Estimate Prostate Volume: A Single-Centre Retrospective Study

2021 ◽  
pp. 1-7
Author(s):  
Matteo Massanova ◽  
Sophie Robertson ◽  
Biagio Barone ◽  
Lorenzo Dutto ◽  
Vincenzo Francesco Caputo ◽  
...  
Keyword(s):  
Radical Prostatectomy ◽  
Prostate Volume ◽  
Transrectal Ultrasound ◽  
Digital Rectal Examination ◽  
Benign Prostatic Hypertrophy ◽  
Volume Measurement ◽  
Surgical Specimen ◽  
Significant Difference ◽  
Ellipsoid Volume

<b><i>Background:</i></b> Prostate volume (PV) is a useful tool in risk stratification, diagnosis, and follow-up of numerous prostatic diseases including prostate cancer and benign prostatic hypertrophy. There is currently no accepted ideal PV measurement method. <b><i>Objective:</i></b> This study compares multiple means of PV estimation, including digital rectal examination (DRE), transrectal ultrasound (TRUS), and magnetic resonance imaging (MRI), and radical prostatectomy specimens to determine the best volume measurement style. <b><i>Methods:</i></b> A retrospective, observational, single-site study with patients identified using an institutional database was performed. A total of 197 patients who underwent robot-assisted radical prostatectomy were considered. Data collected included age, serum PSA at the time of the prostate biopsy, clinical T stage, Gleason score, and PVs for each of the following methods: DRE, TRUS, MRI, and surgical specimen weight (SPW) and volume. <b><i>Results:</i></b> A paired <i>t</i> test was performed, which reported a statistically significant difference between PV measures (DRE, TRUS, MRI ellipsoid, MRI bullet, SP ellipsoid, and SP bullet) and the actual prostate weight. Lowest differences were reported for SP ellipsoid volume (<i>M</i> = −2.37; standard deviation [SD] = 10.227; <i>t</i>[167] = −3.011; and <i>p</i> = 0.003), MRI ellipsoid volume (<i>M</i> = −4.318; SD = 9.53; <i>t</i>[167] = −5.87; and <i>p</i> = 0.000), and MRI bullet volume (<i>M</i> = 5.31; SD = 10.77; <i>t</i>[167] = 6.387; and <i>p</i> = 0.000). <b><i>Conclusion:</i></b> The PV obtained by MRI has proven to correlate with the PV obtained via auto-segmentation software as well as actual SPW, while also being more cost-effective and time-efficient. Therefore, demonstrating that MRI estimated the PV is an adequate method for use in clinical practice for therapeutic planning and patient follow-up.

Mid-aortic syndrome: computed tomography angiography depicting extensive collateral circulation in an 11-year-old patient with thoracoabdominal aortic coarctation

VASA ◽  
2012 ◽  
Vol 41 (2) ◽  
pp. 132-135 ◽  
Author(s):  
Krohn ◽  
Gebauer ◽  
Hübler ◽  
Beck
Keyword(s):  
Computed Tomography ◽  
Computed Tomography Angiography ◽  
Collateral Circulation ◽  
Intestinal Ischemia ◽  
Clinical Presentation ◽  
Lower Limbs ◽  
Upper Body ◽  
Descending Aorta ◽  
Before And After ◽  
Blood Pressures

The mid-aortic syndrome is an uncommon clinical condition characterized by severe narrowing of the descending aorta, usually with involvement of its renal and visceral branches, presenting with uncontrollably elevated blood pressures of the upper body, renal and cardiac failure, intestinal ischemia, encephalopathy symptoms and claudication of the lower limbs, although clinical presentation is variable. In this article we report the case of an eleven-year-old patient with the initial diagnosis of a mid-aortic syndrome and present the computed tomography angiography pictures and reconstructions before and after surgical therapy.

Sign in / Sign up

Export Citation Format

Share Document